Blood Clot Concerns Spur Call to Pause J&J Vaccinations

The CDC and FDA recommended a temporary pause on the use of Johnson & Johnson’s COVID-19 vaccine in the US out of “an abundance of caution” over 6 cases of a rare but severe type of blood clot among recipients, CNN reported this morning.

Key Facts from a joint CDC-FDA statement:

  • The 6 reported cases were among more than 6.8 million Johnson & Johnson vaccine doses administered in the US

  • All 6 cases occurred among women between ages 18-48

  • Symptoms occurred 6-13 days after vaccination

Next Steps:

  • A CDC-convened meeting of the Advisory Committee on Immunization Practices tomorrow will review the cases and assess their significance 

  • The FDA will review that analysis, while continuing its investigation

 
The agencies advise keeping the pause in place until all reviews are complete, to give health providers a chance to plan for the proper recognition and management of these adverse events.

A Reassuring take: “Amid concerns over J&J vaccine, it’s vital to stress that when any vaccine is given to countless millions worldwide, very rare adverse effects will emerge. The benefit/risk ratio is still hugely favorable & far better than virtually any medicine…” tweeted the O’Neill Institute’s Lawrence Gostin.

Comments +

0 comments

Post a Comment

Restricted HTML

  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Back to top